Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9

Abstract

We searched and report mutations in the BRAF and N-ras genes in 22 out of 35 (63 percent) primary sporadic melanomas. In three melanomas, mutations were concomitantly present in both genes. In all, 10 out of 12 mutations in the BRAF gene involved the ‘hot spot’ codon 600 (In all communications on mutations in the BRAF gene, the nucleotide and codon numbers have been based on the NCBI gene bank nucleotide sequence NM_004333. However, according to NCBI gene bank sequence with accession number NT_007914, there is a discrepancy of one codon (three nucleotides) in exon 1 in the sequence with accession number NM_004333. The sequence analysis of exon 1 of the BRAF gene in our laboratory has shown that the sequence derived from NT_007914 is correct (Kumar et al., 2003). Due to the correctness of the latter, sequence numbering of codons and nucleotides after exon 1 are changed by +1 and +3, respectively.), one tandem CT1789-90TC base change represented a novel mutation and another mutation caused a G466R amino-acid change within the glycine-rich loop in the kinase domain. Mutations in the N-ras gene in 11 melanomas were at codon 61 whereas two melanomas carried mutations in codon 12 including a tandem mutation GG>AA. We observed an inverse association between BRAF/N-ras mutations and the frequency of loss of heterozygosity (LOH) on chromosome 9 at 10 different loci. Melanomas with BRAF/N-ras mutations showed a statistically significant decreased frequency of LOH on chromosome 9 compared with cases without mutations (mean fractional allelic loss (FAL)=0.29±0.23 vs 0.72±0.33; t-test, P=0.0001). Difference in the FAL value between tumours with and without BRAF/N-ras mutations on 33 loci on five other chromosomes was not statistically significant (mean FAL 0.17±0.19 vs 0.25±0.22; t-test, P=0.24). Melanoma cases with BRAF/N-ras mutations were also associated with lower age at diagnosis than cases without mutations (mean age 80.38±7.24 vs 65.77±19.79 years; t-test, P=0.02). Our data suggest that the occurrence of BRAF/N-ras mutations compensate the requirement for the allelic loss at chromosome 9, which is one of the key events in melanoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A and Tucker MA . (2002). J. Natl. Cancer Inst., 94, 894–903.

  • Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, Lippman SM, Kripke ML and Ananthaswamy HN . (2003). Clin. Cancer Res., 9, 228–234.

  • Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR and Weber BL . (2002). Cancer Res., 62, 6997–7000.

  • Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP and Ballotti R . (2000). EMBO J., 19, 2900–2910.

  • Castellano M and Parmiani G . (1999). Melanoma Res., 9, 421–432.

  • Chin L, Merlino G and DePinho RA . (1998). Genes Dev., 12, 3467–3481.

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.

  • Demunter A, Stas M, Degreef H, De Wolf-Peeters C and van den Oord JJ . (2001). J. Invest. Dermatol., 117, 1483–1489.

  • Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A and Hansson J . (2003). J. Natl. Cancer Inst., 95, 790–798.

  • Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P and Sander CA . (1998). J. Cutan. Pathol., 25, 291–296.

  • Gilchrest BA, Eller MS, Geller AC and Yaar M . (1999). N. Engl. J. Med., 340, 1341–1348.

  • Halaban R . (2000). Pigment Cell Res., 13, 4–14.

  • Hemminki K, Lonnstedt I and Vaittinen P . (2001). Melanoma Res., 11, 133–140.

  • Hingorani SR and Tuveson DA . (2003). Curr. Opin. Genet. Dev., 13, 6–13.

  • Jiveskog S, Ragnarsson-Olding B, Platz A and Ringborg U . (1998). J. Invest. Dermatol., 111, 757–761.

  • Kolch W . (2000). Biochem. J., 351 (Part 2), 289–305.

  • Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S and Hemminki K . (2003). Clin. Cancer Res. (in press).

  • Kumar R, Lundh Rozell B, Louhelainen J and Hemminki K . (1998a). Int. J. Cancer, 75, 193–198.

  • Kumar R, Sauroja I, Punnonen K, Jansen C and Hemminki K . (1998b). Genes Chromosom. Cancer, 23, 273–277.

  • Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA and Hemminki K . (2001). Int. J. Cancer, 95, 388–393.

  • Kumar R, Smeds J, Lundh Rozell B and Hemminki K . (1999). Melanoma Res., 9, 138–147.

  • Laud K, Kannengiesser C, Avril M-F, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, French Hereditary Melanoma Study Group, Lenoir GM and Bressac-de Paillerets B . (2003). Cancer Res., 63, 3061–3065.

  • Mercer KE and Pritchard CA . (2003). Biochim. Biophys. Acta, 1653, 25–40.

  • Naoki K, Chen TH, Richards WG, Sugarbaker DJ and Meyerson M . (2002). Cancer Res., 62, 7001–7003.

  • Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U and Hansson J . (2002). Clin. Cancer Res., 8, 3468–3474.

  • Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM and Meltzer PS . (2003). Nat. Genet., 33, 19–20.

  • Pollock PM and Meltzer PS . (2002). Cancer Cell, 2, 5–7.

  • Pollock PM, Welch J and Hayward NK . (2001). Cancer Res., 61, 1154–1161.

  • Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE . (2002). Nature, 418, 934.

  • Saida T . (2001). J. Dermatol. Sci., 26, 1–13.

  • Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE and Herlyn M . (2003). Cancer Res., 63, 756–759.

  • Sharpless E and Chin L . (2003). Oncogene, 22, 3092–3098.

  • Shields JM, Pruitt K, McFall A, Shaub A and Der CJ . (2000). Trends Cell. Biol., 10, 147–154.

  • Singer G, Oldt III R, Cohen Y, Wang BG, Sidransky D, Kurman RJ and Shih Ie M . (2003). J. Natl. Cancer Inst., 95, 484–486.

  • Smalley KS . (2003). Int. J. Cancer, 104, 527–532.

  • Smeds J, Kumar R, Rozell BL and Hemminki K . (2000). Mutagenesis, 15, 257–260.

  • van Elsas A, Scheibenbogen C, van der Minne C, Zerp SF, Keilholz U and Schrier PI . (1997). Melanoma Res., 7 (Suppl 2), S107–S113.

  • Walker GJ and Hayward NK . (2002). J. Invest. Dermatol., 119, 783–792.

  • Whiteman DC, Whiteman CA and Green AC . (2001). Cancer Causes Control, 12, 69–82.

  • Yang FC, Merlino G and Chin L . (2001). Semin. Cancer Biol., 11, 261–268.

  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.

  • Zhang BH and Guan KL . (2000). EMBO J., 19, 5429–5439.

Download references

Acknowledgements

We thank Dr. Barbro Lundh-Rozell for providing melanoma samples originally for the CDKN2A studies.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rajiv Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, R., Angelini, S. & Hemminki, K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22, 9217–9224 (2003). https://doi.org/10.1038/sj.onc.1206909

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206909

Keywords

This article is cited by

Search

Quick links